Endo receives outperform rating from Leerink Swann

Endo Pharmaceuticals Holdings Inc. has received an initial rating of outperform from Leerink Swann & Co. analyst Gary Nachman, who based his rating on the launch of oxycodone ER and Lidoderm contributing to near-term earnings growth, a promising market outlook for oxymorphone and a strong product pipeline.

Shares of the Chadds Ford, Pa.-based pharmaceutical company were up $0.20, or 0.78%, at $26.00 on volume of 1,442,329 shares versus the three-month running average of 1,034,980 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.